Apollo Endosurgery completes enrollment in post-approval study of Orbera balloon; shares up 1%

|About: Apollo Endosurgery (APEN)|By:, SA News Editor

Apollo Endosurgery (APEN +1.1%) has completed the enrollment of 281 subjects in a post-approval study of its ORBERA intragastric balloon. Objectives include the percentage of total body weight loss at week 26 and week 52 versus baseline (before receiving the balloon) and safety measures. Final data should be available in early 2020.

Subscribe for full text news in your inbox